Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2044-5385

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients ; volume:10 ; number:11 ; day:9 ; month:11 ; year:2020 ; pages:1-8 ; date:11.2020
Blood cancer journal ; 10, Heft 11 (9.11.2020), 1-8, 11.2020

Creator: Krull, Jordan E.
Wenzl, Kerstin
Hartert, Keenan T.
Manske, Michelle K.
Sarangi, Vivekananda
Maurer, Matthew J.
Larson, Melissa C.
Nowakowski, Grzegorz S.
Ansell, Stephen M.
McPhail, Ellen
Habermann, Thomas M.
Link, Brian K.
King, Rebecca L.
Cerhan, James R.
Novak, Anne J.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41408-020-00382-3

URN: urn:nbn:de:101:1-2020122020445803618049

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:38 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Krull, Jordan E.
Wenzl, Kerstin
Hartert, Keenan T.
Manske, Michelle K.
Sarangi, Vivekananda
Maurer, Matthew J.
Larson, Melissa C.
Nowakowski, Grzegorz S.
Ansell, Stephen M.
McPhail, Ellen
Habermann, Thomas M.
Link, Brian K.
King, Rebecca L.
Cerhan, James R.
Novak, Anne J.
SpringerLink (Online service)

Other Objects (12)

$Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)$

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

$Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)$

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

$Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)$

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2

GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner

Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement

Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma

50% versus 70%: is there a difference between these BCL2 cut-offs in immunohistochemistry for diffuse large B-cell lymphomas (DLBCL)?

Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level

c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency

Related objects

Reset password